

# RHA® 3: Now FDA Approved for Lips

Designed for **dynamic volume** in the lips and the dynamic wrinkles and folds around them<sup>1,2\*</sup>



## Discover dynamic possibilities

### MOST POPULAR TREATMENT AREA



The lips are the most popular dermal filler treatment area<sup>3</sup>

### ONE OF THE MOST DYNAMIC AREAS



The perioral area is one of the most dynamic facial areas, requiring a dynamic filler<sup>2,4-6</sup>

### FIRST AND ONLY



The first and only FDA-approved filler for both lips and dynamic wrinkles and folds<sup>1</sup>

# The D-N-A of RHA<sup>®</sup> 3

## D DYNAMIC

- Unique balance of **dynamic strength and stretch**<sup>2</sup>
- Robust enough to add **long-lasting fullness** to the lips while maintaining a **natural look and feel**<sup>1,7</sup>

## N NATURAL

- Made to more closely resemble **natural hyaluronic acid (HA)**<sup>2,8</sup>
- More than **92% of subjects** rated their lips as looking and feeling natural at **1 year** in the pivotal study<sup>7</sup>

## A ADAPTABLE

- Designed to **adapt to dynamic movement**; well-suited for the lips and surrounding areas<sup>2,9</sup>

# Age-related changes in the lips<sup>10-13</sup>



### SIDE VIEW:

- Inversion of the lips
- Loss of anterior projection



### FRONTAL VIEW:

- Lengthening of cutaneous upper lip
- Development of rhytids
- Flattening of cupid's bow and philtral column

# Two *dynamic* formulations

Treat the lips and surrounding areas with two RHA<sup>®</sup> fillers designed for dynamic facial movement.<sup>1,2</sup>

## RHA<sup>®</sup> 3

Dynamic volume in the lips and the dynamic wrinkles/folds around them<sup>1</sup>

Unique balance of dynamic strength and stretch<sup>2</sup>

## RHA Redensity<sup>™</sup>

Fine-tuned finish for perioral rhytids<sup>1</sup>

Highest stretch of all HA fillers in the US market<sup>2</sup>

DYNAMIC STRENGTH SCORE (PA<sup>2</sup>)<sup>2,15</sup>

31900 RHA<sup>®</sup> 3

4390 RHA Redensity<sup>™</sup>


STRETCH SCORE (%/s)<sup>2,15</sup>

85.3

792

# A modern approach to lip rejuvenation

- **Facial aging** involves changes in the lower face leading to **lines and wrinkles** as well as **loss of shape and volume in the lips**<sup>14</sup>
- Modern injection strategies consider **the lips as part of the whole face**. It's essential to **treat both the lips and the surrounding areas** for a comprehensive outcome<sup>10</sup>



- A. Nasolabial Folds (NLFs): RHA<sup>®</sup> 3**
- B. Marionettes: RHA<sup>®</sup> 3**
- C. Oral Commissures: RHA<sup>®</sup> 3**
- D. Lips: RHA<sup>®</sup> 3**
- E. Mental Crease: RHA<sup>®</sup> 3**
- F. Perioral Lines: RHA Redensity<sup>™</sup>**

Other RHA<sup>®</sup> formulations (RHA<sup>®</sup> 2 and RHA<sup>®</sup> 4) are also indicated for moderate to severe dynamic wrinkles and folds, such as those listed here.<sup>1</sup>

# Dynamic fillers for one of the most *dynamic* facial areas<sup>1,2,4-6</sup>

## RHA® 3

For lips and the dynamic wrinkles/folds around them<sup>1</sup>



## RHA Redensity™

For perioral rhytids<sup>1</sup>

**NATURAL LOOK AND FEEL<sup>7,16</sup> | HIGH SATISFACTION<sup>1</sup> | RESULTS LAST UP TO 1 YEAR<sup>1</sup>**

### PLEASE SEE FULL DIRECTIONS FOR USE

#### RHA® COLLECTION OF FILLERS

**INDICATIONS:** The RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity™, RHA® 2, RHA® 3 and RHA® 4. RHA Redensity™ is indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older. RHA® 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds and is also indicated for injection into the vermilion body, vermilion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older.

#### IMPORTANT SAFETY INFORMATION

**CONTRAINDICATIONS:** Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine. Do not use in patients with bleeding disorders.

**WARNINGS:** Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur. Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

**PRECAUTIONS:** These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy. Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications. The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies. As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed. The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied. Use with caution in patients on immunosuppressive therapy. Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites. Patients with a history of herpetic eruptions may experience reactivation of the herpes. There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment. Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product. For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

**ADVERSE EVENTS:** The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. To report an adverse reaction with any RHA® product, please call Revance at (877) 373-8669.

RHA-P-002436.3

**REFERENCES:** 1. RHA® Directions for Use. Nashville, TN: Revance Therapeutics, Inc, 2023. 2. Favier J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Advanced concepts in rheology for the evaluation of hyaluronic acid-based soft tissue fillers. *Dermatol Surg.* 2021;47(5):159-167. 3. Data on file. Qsight Aesthetics Tracker: Dermal Fillers. Newark, CA: Revance Therapeutics, Inc, 2023. 4. Chang CS, Chang BL, Lanni M, Wilson AJ, Beer J, Percec I. Perioral rejuvenation: a prospective, quantitative dynamic three-dimensional analysis of a dual modality treatment. *Aesthet Surg J.* 2018;38(11):1225-1236. 5. Akinbiyi T, Othman S, Familiusi O, Calvert C, Card EC, Percec I. Better Results in Facial Rejuvenation with Fillers. *Plast Reconstr Surg Glob Open.* 2020;8(10):e2763. 6. Swift A and Remington BK. The Mathematics of Facial Beauty. In: Jones D, Swift A, eds. *Injectable Fillers: Facial Shaping and Contouring.* 2nd ed. Wiley Blackwell; 2019: 29-61. 7. RHA® Patient Labeling. Nashville, TN: Revance Therapeutics, Inc, 2023. 8. Monheit G, Kaufman-Janette J, Joseph JH, Shamban A, Dover JS, Smith S. Efficacy and safety of two resilient hyaluronic acid fillers in the treatment of moderate-to-severe nasolabial folds: A 64-week, prospective, multicenter, controlled, randomized, double-blinded, and within-subject study. *Dermatol Surg.* 2020;46(12):1521-1529. 9. Michaud T, Gassia V, Belhaouari L. Facial dynamics and emotional expressions in facial aging treatments. *J Cosmet Dermatol.* 2015;14(1):9-21. 10. Humphrey S. The lips. In: Jones D, Swift A, eds. *Injectable Fillers: Facial Shaping and Contouring.* 2nd ed. Wiley Blackwell; 2019: 149-163. 11. Sarnoff DS, Gotkin RH. Six steps to the "perfect" lip. *J Drugs Dermatol.* 2012;11(9):1081-1088. 12. Ramaut, L, Tonnard P, Verpaele A, Verstraete K, Blondeel P. Aging of the upper lip: Part I: A retrospective analysis of metric changes in soft tissue on magnetic resonance imaging. *Plast Reconstr Surg.* 2019;143(2):440-446. 13. Tonnard PL, Verpaele AM, Ramaut LE, Blondeel PN. Aging of the upper lip: Part II: Evidence-based rejuvenation of the upper lip—A review of 500 consecutive cases. *Plast Reconstr Surg.* 2019;143(5):1333-1342. 14. Wollina U. Perioral rejuvenation: restoration of attractiveness in aging females by minimally invasive procedures. *Clin Interv Aging.* 2013;8:1149-1155. 15. Data on file. RDRE 2016—US Products, 2016. Newark, CA: Revance Therapeutics, Inc, 2016. 16. Sundaram H, Shamban A, Schlessinger J et al. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderate-to-severe dynamic perioral rhytides: A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. *Dermatol Surg.* 2022;48(1):87-93.